Nuclear Fructose‐1,6‐Bisphosphate Inhibits Tumor Growth and Sensitizes Chemotherapy by Targeting HMGB1
Advanced Science · 2023-03 · 10 (7)
DOI: 10.1002/advs.202203528 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 15.01.2023. Verfasst von Yeyi Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin…. Hauptthemen laut MEDLINE: HMGB1 Protein, Neoplasms, Fructosediphosphates. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Nature Science Foundation of China, Tianjin Municipal Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Metabolites are important for cell fate determination. Fructose‐1,6‐bisphosphate (F1,6P) is the rate‐limiting product in glycolysis and the rate‐limiting substrate in gluconeogenesis. Here, it is discovered that the nuclear‐accumulated F1,6P impairs cancer cell viability by directly binding to high mobility group box 1 (HMGB1), the most abundant non‐histone chromosome structural protein with paradoxical roles in tumor development. F1,6P disrupts the association between the HMGB1 A‐box and C‐tail by targeting K43/K44 residues, inhibits HMGB1 oligomerization, and stabilizes P53 protein by increasing P53–HMGB1 interaction. Moreover, F1,6P lowers the affinity of HMGB1 for DNA and DNA adducts, which sensitizes cancer cells to chemotherapeutic drug(s)‐induced DNA replication stress and DNA damage. Concordantly, F1,6P resensitizes cancer cells with chemotherapy resistance, impairs tumor growth and enhances chemosensitivity in mice, and impedes the growth of human tumor organoids. These findings reveal a novel role for nuclear‐accumulated F1,6P and underscore the potential utility of F1,6P as a drug for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Lung Cancer Center, Department of Thoracic Oncology, Tianjin Cancer I…
- Center for Mitochondrial Biology & Medicine, the Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China.
- The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory of Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education…
- Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China.
ORCID-Profile: Ting Wang
Förderung
- National Nature Science Foundation of China
- Tianjin Municipal Natural Science Foundation of China
Zitieren
APA
Li, Y., Fu, Y., Zhang, Y., Duan, B., Zhao, Y., Shang, M., Cheng, Y., Zhang, K., Yu, Q., & Wang, T. (2023). Nuclear Fructose‐1,6‐Bisphosphate Inhibits Tumor Growth and Sensitizes Chemotherapy by Targeting HMGB1. Advanced Science, 10(7). https://doi.org/10.1002/advs.202203528
Vancouver
Li Y, Fu Y, Zhang Y, Duan B, Zhao Y, Shang M, et al. Nuclear Fructose‐1,6‐Bisphosphate Inhibits Tumor Growth and Sensitizes Chemotherapy by Targeting HMGB1. Advanced Science. 2023;10(7). doi:10.1002/advs.202203528
BibTeX
@article{Li2023,
author = {Li, Yeyi and Fu, Yuan and Zhang, Yan and Duan, Bilian and Zhao, Yanli and Shang, Man and Cheng, Ying and Zhang, Kai and Yu, Qiujing and Wang, Ting},
title = {Nuclear Fructose‐1,6‐Bisphosphate Inhibits Tumor Growth and Sensitizes Chemotherapy by Targeting HMGB1},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {7},
doi = {10.1002/advs.202203528}
}
EUVIMED